BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...immune cells. It’s ligand, CD155, plays different roles depending on the receptor it binds. When CD155...
...express the TIGIT target at higher densities than other immune cells. Targets: CD155 (PVR) - Poliovirus receptor...
...superfamily 9 HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 CD155 (PVR) - Poliovirus receptor...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

...death 1 PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 PVRIG (CD112R) - Poliovirus receptor...
BioCentury | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

...In PULSAR, sotatercept plus SOC led to a statistically significant reduction in pulmonary vascular resistance (PVR...
...secondary endpoint, vs. SOC alone. The trial was powered to detect an 18% reduction in PVR...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...ligand 1 PD-L2 (PDCD1LG2, B7-DC) - Programmed cell death 1 ligand 2 PVRIG (CD112R) - Poliovirus receptor...
...GITR) (TNFRSF18) Inducible T cell co-stimulator (ICOS) Lymphocyte-activation gene 3 (LAG3) (CD223) Programmed cell death 1 (PD-1) (PDCD1) (CD279) Poliovirus receptor...
BioCentury | Mar 8, 2019
Company News

Compugen cuts workforce by 35%

...and will continue to advance its earlier stage immuno-oncology pipeline. COM701 is a mAb targeting poliovirus receptor...
BioCentury | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

...Rises After Hours on Phase II PAH Data” ). Uptravi led to statistically significant mean PVR...
BioCentury | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

...Rises After Hours on Phase II PAH Data” ). Uptravi led to statistically significant mean PVR...
BioCentury | Oct 12, 2018
Company News

Compugen partners with BMS for Phase I combo trial of its first-in-class checkpoint inhibitor

...plus BMS's anti-PD-1 mAb Opdivo nivolumab for advanced solid tumors. COM701 targets new checkpoint target poliovirus receptor...
...Holon, Israel Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Jennie Walters COM701, cgen-15029 Bristol-Myers Squibb Co. Compugen Ltd. Poliovirus receptor...
BioCentury | Aug 24, 2018
Targets & Mechanisms

Computing checkpoints

...cell death 1 ligand 1; PVRIG (CD112R) - Poliovirus receptor related immunoglobulin domain containing; PVRL2 - Poliovirus receptor-related...
...expression of PVR or PD-L1,” Compugen spokesperson Tsipi Haitovsky told BioCentury in an emailed statement. PVR...
...1 PRVIG (CD112R) - Poliovirus receptor related immunoglobulin domain containing PVR (CD155) - Poliovirus receptor PVRL2 - Poliovirus receptor-related...
BioCentury | Jul 17, 2018
Distillery Therapeutics

Cancer

...studies suggest inhibiting PVR could help treat cancer. In patient tissue samples, tumor levels of PVR...
...increased survival compared with normal PVR expression. In two mouse models of metastatic melanoma, systemic PVR...
...steps could include identifying and testing PVR inhibitors in models of cancer. TARGET/MARKER/PATHWAY: Poliovirus receptor (PVR; CD155...
Items per page:
1 - 10 of 70